 Fibrosis is a condition where there is an imbalance between extracellular matrix deposition and degradation, resulting in scarring and thickening of affected tissue, and interfering with tissue and organ homeostasis. TGF-beta ligands are potent drivers of ECM deposition and upregulated in many human fibrotic conditions, making them attractive targets for fibrosis therapy. This article was authored by Kelly L. Walton, Catherine E. Johnson and Craig A. Harrison.